Coherus BioSciences Files Proxy Statement

Ticker: CHRS · Form: DEFA14A · Filed: Jan 14, 2025 · CIK: 1512762

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

Related Tickers: CHRS

TL;DR

Coherus BioSciences (CHRS) filed its proxy statement - expect votes on directors and pay soon.

AI Summary

Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on January 14, 2025. This filing is related to the company's annual meeting and likely concerns the election of directors, executive compensation, and other corporate governance matters. The company, previously known as BioGenerics, Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, executive pay, and voting matters, enabling them to make informed decisions at the upcoming shareholder meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating any immediate financial distress or significant corporate event.

Key Players & Entities

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, typically to vote on matters such as director elections, executive compensation, and other corporate governance issues.

When was this proxy statement filed?

This Definitive Proxy Statement was filed on January 14, 2025.

What was Coherus BioSciences, Inc. previously named?

Coherus BioSciences, Inc. was formerly known as BioGenerics, Inc.

Where is Coherus BioSciences, Inc. incorporated?

Coherus BioSciences, Inc. is incorporated in Delaware (DE).

What is the primary business of Coherus BioSciences, Inc. according to the filing?

According to the filing, Coherus BioSciences, Inc. operates in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, with SIC code 2836.

Filing Stats: 4,874 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-01-13 20:45:54

Key Financial Figures

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ​ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ​ Definitive Proxy Statement ​ ​ Definitive Additional Materials ​ ​ Soliciting Material under §240.14a-12 Coherus BioSciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. ​ ​ Fee paid previously with preliminary materials. ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 43rd Annual J.P. Morgan Healthcare Conference January 2025 Forward Looking Statements 2 2025 Coherus BioSciences Except for the historical information contained herein, the matters set forth in this presentation are forward - looking statement s within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements about the agreement to sell Coheru s' UDENYCA franchise to Intas Pharmaceuticals Ltd. and related matters, including, but not limited to, the ability to satisfy the closing conditions to consummate the proposed tran sac tion at all or in the estimated time; prospective performance and opportunities with respect to Coherus or the UDENYCA franchise; post - closing operations and the outlook for Cohe rus or the UDENYCA franchise; the Company's targets, plans, objectives or goals for future operations, including those related to the UDENYCA franchise, product candidat es, research and development, and product candidate approvals; future receipt of sales milestone payments from the proposed transaction to sell the UDENYCA franchise; projection s o f reductions in future indebtedness; projections of Coherus' cash runway in the future; statements about the potential uses of proceeds from the transaction to sell the UDENYCA fra nchise, statements about future clinical events, catalysts and data readouts, statements about growth in sales or revenues and Coherus' future balance sheet, estimates of mar ket opportunity, market value and treatable patients or cases, statements about sales or revenue ramp, statements about expected 2024 total year and Q4 2024 expected net revenues an d s ales, and expected 2024 year - end cash, cash equivalents and investments, and the assumptions underlying or relating to such statements. Such forward - looking statements invo lve substantial risks and uncertainties that could cause Coherus' actual results, performance or achievements to differ significantly from any future results, performance or ac hie vements expressed or implied by the forward - looking statements. Such risks and uncertainties include, among others, uncertainties as to the timing for completion of the proposed tr ansaction to sell the UDENYCA franchise; uncertainties as to the Company's ability to obtain the approval of its shareholders required to consummate the proposed transaction to sel l t he UDENYCA franchise; the possibility that competing offers will be made by third parties; uncertainties of receipt of sales milestone payments in the future; the occurrence of a ny event, change or other circumstance that may give rise to a right of one or both of parties to terminate the asset purchase agreement; the possibility that the proposed transaction to se ll the UDENYCA franchise may not be completed in the time frame expected by the Company or at all, including due to the possibility that a governmental entity may prohibit, delay , o r refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the risk that th e proposed transaction disrupts the Company's current plans and operations or diverts the attention of the Company's management or employees from ongoing business operations; the ris k that the Company may not realize the anticipated benefits of the proposed transaction to sell the UDENYCA franchise in the time frame expected, or at all; the eff ect s of the proposed transaction on relationships with the Company's employees, suppliers, business or collaboration partners or governmental entities, or other third parties as a resu lt of the proposed transaction; the ability to retain and hire key personnel; significant or unexpected costs, charges or expenses resulting from the propos

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing